Suggested remit: To appraise the clinical and cost effectiveness of histamine dihydrochloride with interleukin-2 within its marketing authorisation for maintenance treatment of acute myeloid leukaemia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 1627
Provisional Schedule
- Committee meeting: 1:
- 04 February 2026
- Expected publication:
- 22 April 2026
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Brancaster Pharma
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer 52
- Cancer Black Care
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- WMUK
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Surgeons of Great Britain and Ireland
- British Association of Surgical Oncology
- British Blood Transfusion Society
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Blood and Marrow Transplantation and Cellular Therapy
- British Society of Interventional Radiology
- British Transplantation Society
- Cancer Research UK
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK CLL Forum
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Clinigen Healthcare (interleukin-2)
- Accord Healthcare (cytarabine, sorafenib)
- Bayer (sorafenib)
- Bristol Myers Squibb (azacitidine)
- Daiichi Sankyo (quizartinib)
- Hospira UK (cytarabine)
- Jazz Pharmaceuticals (cytarabine)
- Napp Pharmaceuticals (cytarabine)
- Novartis Pharmaceuticals (midostaurin)
- Pfizer (cytarabine)
- Sandoz (sorafenib)
- Teva UK (sorafenib)
- Thornton & Ross (sorafenib)
- Zentiva UK (sorafenib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Hospital Information Services –Jehovah’s Witnesses
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematological Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Lymphoma Research Trust
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 02 July 2025 | Invitation to participate |
| 22 May 2025 - 20 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1627 |
| 22 May 2025 | In progress. Scoping commencing |
| 06 February 2025 | As you will be aware The Department for Health & Social Care has asked NICE to conduct an appraisal of Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] Please note that following on from a request received from the company this appraisal have been scheduled into the work programme and the appraisal is now anticipated to begin during early July 2025 when we will write to you about how you can get involved. |
| 26 June 2020 | Suspended: The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia ID1627. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that markets histamine dihydrochloride have ceased to engage with NICE regarding this appraisal. NICE have therefore taken the decision to suspend this topic from the work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please contact the project manager for this appraisal Emily Richards on (44 (0)161 413 4070 or via email on [email protected]) |
| 26 June 2020 | Suspended. _ |
For further information on our processes and methods, please see our CHTE processes and methods manual